Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Kinesin Like Protein KIF11 Therapeutic Pipeline Market Review, H2 2016

Thursday, October 20, 2016 0:48
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Pipeline Review, H2 2016’, provides in depth analysis on Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted pipeline therapeutics.

Request a sample report @ https://www.wiseguyreports.com/sample-request/693281-kinesin-like-protein-kif11-review-h2-2016

The report provides comprehensive information on the Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics development and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) 
- The report reviews Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) 
- Identify the use of drugs for target identification and drug repurposing 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/693281-kinesin-like-protein-kif11-review-h2-2016   

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Report Coverage 6 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) Overview 7 
Therapeutics Development 8 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Products under Development by Stage of Development 8 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Products under Development by Therapy Area 9 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Products under Development by Indication 10 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Pipeline Products Glance 12 
Late Stage Products 12 
Early Stage Products 13 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Products under Development by Companies 14 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Products under Development by Universities/Institutes 16 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Therapeutics Assessment 18 
Assessment by Monotherapy/Combination Products 18 
Assessment by Mechanism of Action 19 
Assessment by Route of Administration 20 
Assessment by Molecule Type 22 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Companies Involved in Therapeutics Development 24 
4SC AG 24 
Alnylam Pharmaceuticals, Inc. 25 
Array BioPharma Inc. 26 
Kyowa Hakko Kirin Co., Ltd. 27 
Merck & Co., Inc. 28 
Novartis AG 29 
Pfizer Inc. 30 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Drug Profiles 31 
4SC-205 – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
ALN-VSP – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
BIND-267 – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
BQS-481 – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
filanesib – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
LH-025 – Drug Profile 42 
Product Description 42 
Mechanism Of Action 42 
R&D Progress 42 
MK-8267 – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
Small Molecule to Inhibit Kinesin Spindle Protein for Cancer – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Small Molecules to Inhibit Eg5 for Immunology and Oncology – Drug Profile 46 
Product Description 46 
Mechanism Of Action 46 
R&D Progress 46 
Small Molecules to Inhibit KSP for Oncology – Drug Profile 47 
Product Description 47 
Mechanism Of Action 47 
R&D Progress 47 
Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
SRI-35566 – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Dormant Projects 50 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Discontinued Products 53 
Kinesin Like Protein KIF11 (Kinesin Like Protein 1 or Kinesin Like Spindle Protein HKSP or Kinesin Related Motor Protein Eg5 or Thyroid Receptor Interacting Protein 5 or TRIP5 or EG5 or KIF11) – Featured News & Press Releases 55 
Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO 55 
Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme 56 
Jul 29, 2013: Motor Protein Revs Up Cell Division 58 
Jun 17, 2013: Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At 2013 European Hematology Association Congress 58 
Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi’s Research 60 
Apr 04, 2013: Array BioPharma Presents Results From Two Ongoing ARRY-520 Clinical Trials In Multiple Myeloma At 2013 International Myeloma Workshop 60 
Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery 62 
Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer 62 
Dec 11, 2012: Array BioPharma Provides Updates On Clinical Data On ARRY-520 At 2012 American Society Of Hematology Meeting 64 
Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment 65 
Nov 05, 2012: Array BioPharma To Present Clinical Data On ARRY-520 At 2012 ASH Meeting 66 
Jun 04, 2012: Alnylam Presents Results From Phase I Extension Study Of ALN-VSP At ASCO 2012 Annual Meeting 68 
Mar 14, 2012: Tekmira Provides Update On Progress In USPTO Patent Interference Proceedings Related To Alnylam’s ALN-VSP 69 
Dec 11, 2011: Array BioPharma’s ARRY-520 Demonstrates Durable Single-Agent Activity In Patients With Advanced Multiple Myeloma 70 
Nov 29, 2011: Array Biopharma To Present Clinical Data On ARRY-520 At 2011 American Society Of Hematology Annual Meeting 71 
Appendix 72 
Methodology 72 
Coverage 72 
Secondary Research 72 
Primary Research 72 
Expert Panel Validation 72 
Contact Us 72 
Disclaimer 73

List of Tables 
Number of Products under Development for, H2 2016 8 
Number of Products under Development by Therapy Area, H2 2016 9 
Number of Products under Development by Indication, H2 2016 11 
Comparative Analysis by Late Stage Development, H2 2016 12 
Comparative Analysis by Early Stage Products, H2 2016 13 
Number of Products under Development by Companies, H2 2016 14 
Products under Development by Companies, H2 2016 15 
Number of Products under Investigation by Universities/Institutes, H2 2016 16 
Products under Investigation by Universities/Institutes, H2 2016 17 
Assessment by Monotherapy/Combination Products, H2 2016 18 
Number of Products by Stage and Mechanism of Action, H2 2016 19 
Number of Products by Stage and Route of Administration, H2 2016 21 
Number of Products by Stage and Molecule Type, H2 2016 23 
Pipeline by 4SC AG, H2 2016 24 
Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 25 
Pipeline by Array BioPharma Inc., H2 2016 26 
Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 27 
Pipeline by Merck & Co., Inc., H2 2016 28 
Pipeline by Novartis AG, H2 2016 29 
Pipeline by Pfizer Inc., H2 2016 30 
Dormant Projects, H2 2016 50 
Dormant Projects (Contd..1), H2 2016 51 
Dormant Projects (Contd..2), H2 2016 52 
Discontinued Products, H2 2016 53 
Discontinued Products (Contd..1), H2 2016 54

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=693281

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)           

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.